Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia

Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Sulfonamides / therapeutic use

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • venetoclax